Surveillance of adverse events following immunisation in Australia annual report, 2022
Communicable Diseases Intelligence · 2025
DOI: 10.33321/cdi.2025.49.043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2025. Verfasst von Yuanfei Anny Huang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Immunisation Research and Surveillance, Locked Bag 4001, Westmead NSW 2145, Sydney, Australia. yuanfei.huang@health.nsw.gov.au. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, COVID-19, Vaccination, COVID-19 Vaccines. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
This report summarises Australia’s spontaneous surveillance data for non-COVID-19 vaccine adverse events following immunisation (AEFI) for 2022, reported to the Therapeutic Goods Administration (TGA). National spontaneous (passive) surveillance data for coronavirus disease 2019 (COVID-19) vaccine AEFI reported to the TGA are analysed and discussed in a separate companion publication. There were 3,642 AEFI reports for non-COVID-19 vaccines administered in 2022, representing an annual AEFI reporting rate of 14.0 per 100,000 population, compared with 13.4 per 100,000 population in 2021. This very small increase in the AEFI reporting rate in 2022 could potentially be related to the combination of several factors: a gradual return to pre-pandemic AEFI reporting patterns; new vaccination programs in response to outbreaks of emergent vaccine preventable diseases (Japanese encephalitis and mpox); and a change in the reporting activities of pharmaceutical sponsors. AEFI reporting rates for individual vaccines in 2022 were similar to 2021.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Immunisation Research and Surveillance, Locked Bag 4001, Westmead NSW 2145, Sydney, Australia. yuanfei.huang@health.nsw.gov.au.
- Pharmacovigilance Branch, Therapeutic Goods Administration, Department of Health, Disability and Ageing, Canberra, Australia.
- National Centre for Immunisation Research and Surveillance, The University of Sydney and The Children's Hospital at Westmead, Sydney, Australia.
Zitieren
APA
Huang, Y. A., Larter, C., Hickie, M., O'Moore, M., Jones, B., Deng, L., Russell, S., Kay, E., Macartney, K., & Wood, N. (2025). Surveillance of adverse events following immunisation in Australia annual report, 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2025.49.043
Vancouver
Huang YA, Larter C, Hickie M, O'Moore M, Jones B, Deng L, et al. Surveillance of adverse events following immunisation in Australia annual report, 2022. Communicable Diseases Intelligence. 2025. doi:10.33321/cdi.2025.49.043
BibTeX
@article{Huang2025,
author = {Huang, Yuanfei Anny and Larter, Claire and Hickie, Megan and O'Moore, Megan and Jones, Belinda and Deng, Lucy and Russell, Sophie and Kay, Elspeth and Macartney, Kristine and Wood, Nicholas},
title = {Surveillance of adverse events following immunisation in Australia annual report, 2022},
journal = {Communicable Diseases Intelligence},
year = {2025},
doi = {10.33321/cdi.2025.49.043}
}
EUVIMED